The Biologics Market on a global scale was estimated at USD 426.1 Bn in 2024 and is projected to attain USD 890.2 Bn by 2034, with a projected CAGR of 7.8% between 2025 and 2034.
Biologics covers drugs manufactured from organic materials that can treat various disorders, including immune-related illnesses such as crohn's disease, psoriasis, ankylosing spondylitis, and rheumatoid . Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
The market's upward path is supported by mounting healthcare spending, technological evolution, and the mounting focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold pronounced shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Biologics Market Snapshot
Chapter 4. Global Biologics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Route of Administration Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Source Estimates & Trend Analysis
5.1. by Source & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Source:
5.2.1. Microbial
5.2.2. Mammalian
5.2.3. Others
Chapter 6. Market Segmentation 2: by Product Estimates & Trend Analysis
6.1. by Product & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product:
6.2.1. MABs
6.2.2. Vaccines
6.2.3. Hormones
6.2.4. Therapeutic Enzymes
6.2.5. Recombinant Proteins
6.2.6. Antisense, RNAi & Molecular Therapy
6.2.7. Blood Factors and Anticoagulants
6.2.8. Allergenic extracts
6.2.9. Human Cells and Tissues
6.2.10. Proteins
6.2.11. Gene Therapies
6.2.12. Cellular Therapies
6.2.13. Others
Chapter 7. Market Segmentation 3: by Disease Estimates & Trend Analysis
7.1. by Disease & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Disease:
7.2.1. Oncology
7.2.2. Immunological Disorders
7.2.3. Cardiovascular Disorders
7.2.4. Hematological Disorders
7.2.5. Others
Chapter 8. Market Segmentation 4: by Manufacturing Estimates & Trend Analysis
8.1. by Manufacturing & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Manufacturing:
8.2.1. Outsourced
8.2.2. In-house
Chapter 9. Market Segmentation 5: by Distribution Channel Estimates & Trend Analysis
9.1. by Distribution Channel & Market Share, 2024 & 2034
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Distribution Channel:
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
Chapter 10. Market Segmentation 6: by Route of Administration Estimates & Trend Analysis
10.1. by Route of Administration& Market Share, 2024 & 2034
10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Route of Administration:
10.2.1. Oral
10.2.2. Others (IV and IP)
Chapter 11. Market Segmentation 7: by Drug Classification Estimates & Trend Analysis
11.1. by Drug Classification & Market Share, 2024 & 2034
11.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Drug Classification:
11.2.1. Branded Drugs
11.2.2. Generic Drugs
Chapter 12. Market Segmentation 8: by Mode of Purchase Estimates & Trend Analysis
12.1. by Mode of Purchase & Market Share, 2024 & 2034
12.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Mode of Purchase:
12.2.1. Prescription Drugs
12.2.2. Over The Counter (OTC) Drugs
Chapter 13. Biologics Market Segmentation 9: Regional Estimates & Trend Analysis
13.1. North America
13.1.1. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
13.1.2. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
13.1.3. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
13.1.4. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2021-2034
13.1.5. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
13.1.6. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
13.1.7. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2021-2034
13.1.8. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2021-2034
13.1.9. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
13.2. Europe
13.2.1. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
13.2.2. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
13.2.3. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
13.2.4. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2021-2034
13.2.5. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
13.2.6. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
13.2.7. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2021-2034
13.2.8. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2021-2034
13.2.9. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
13.3. Asia Pacific
13.3.1. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
13.3.2. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
13.3.3. Asia-Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
13.3.4. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2021-2034
13.3.5. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
13.3.6. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
13.3.7. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2021-2034
13.3.8. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2021-2034
13.3.9. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
13.4. Latin America
13.4.1. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
13.4.2. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
13.4.3. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
13.4.4. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2021-2034
13.4.5. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
13.4.6. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
13.4.7. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2021-2034
13.4.8. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2021-2034
13.4.9. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
13.5. Middle East & Africa
13.5.1. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
13.5.2. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
13.5.3. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
13.5.4. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2021-2034
13.5.5. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
13.5.6. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
13.5.7. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2021-2034
13.5.8. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2021-2034
13.5.9. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 14. Competitive Landscape
14.1. Major Mergers and Acquisitions/Strategic Alliances
14.2. Company Profiles
14.2.1. Abbvie Inc.
14.2.2. Amgen
14.2.3. AstraZeneca
14.2.4. Bayer AG
14.2.5. Celltrion Inc.
14.2.6. Addgene
14.2.7. Eli Lilly & Company
14.2.8. F. Hoffmann-La Roche Ltd
14.2.9. GSK group of companies
14.2.10. Johnson & Johnson Services, Inc
14.2.11. Merck & Co. Inc
14.2.12. Novartis AG
14.2.13. Novo Nordisk A/S
14.2.14. Pfizer Inc.
14.2.15. Precision Biologics, Inc.
14.2.16. Samsung Biologics
14.2.17. Sanofi
14.2.18. Other Prominent Players